New combo therapy aims to shield kidneys in african american veterans

NCT ID NCT07155694

Not yet recruiting Disease control Sponsor: Washington D.C. Veterans Affairs Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests two drugs, finerenone and empagliflozin, in 30 African American veterans with diabetic kidney disease. The goal is to see if these drugs reduce kidney cell damage by measuring specific proteins in urine. Participants will take one or both drugs for 4 months to check for protective effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Finerenone (Kerendia) and Empagliflozin (Jardiance)
What this could lead to: If successful, this could show that finerenone, alone or with empagliflozin, helps protect kidney health in African American veterans with diabetic kidney disease.
What could go wrong: This is a small early-phase trial with only 30 participants, so results may not apply to everyone. The study looks at markers in urine, not long-term outcomes like kidney failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome diabetes mellitus diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE

Contacts and locations

Locations

Washington DC Veterans Affairs Medical Center (688)

Washington D.C., District of Columbia, 20422, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.